EQL Pharma AB (publ) (STO:EQL)

Market Cap	2.38B
Revenue (ttm)	397.94M
Net Income (ttm)	42.54M
Shares Out	29.06M
EPS (ttm)	1.41
PE Ratio	58.05
Forward PE	39.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,433
Average Volume	34,672
Open	81.40
Previous Close	82.00
Day's Range	80.90 - 82.50
52-Week Range	51.00 - 98.60
Beta	0.64
RSI	38.65
Earnings Date	Nov 5, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.